News
Adding the immune checkpoint inhibitor durvalumab (Imfinzi) to the standard chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) improved event-free survival (EFS) in ...
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback